ArticleAmerican journal of respiratory and critical care medicine2020
Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 47 citations in OpenAlex.
- Male reproductive phenotype in cystic fibrosis: comparison of existing animal models.Lab animal · 2026Review
- PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats.bioRxiv : the preprint server for biology · 2026Article
- Repurposing ivacaftor to attenuate LPS-induced acute lung injury: evidence from a non-cystic fibrosis model.Frontiers in pharmacology · 2026Article
- Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD).Journal of clinical medicine · 2025Review
- Article
- Mapping the oxidative landscape in cystic fibrosis: methodological frontiers and application.Frontiers in pharmacology · 2025Review
- Evaluating the effects of ivacaftor exposure onJAC-antimicrobial resistance · 2024Article
- Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats.Respiratory research · 2024Article
- Lentiviral vector gene therapy and CFTR modulators show comparable effectiveness in cystic fibrosis rat airway models.Gene therapy · 2024Article
- Normalization of Muc5b ameliorates airway mucus plugging during persistentAmerican journal of physiology. Lung cellular and molecular physiology · 2024Article
- Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.Journal of fungi (Basel, Switzerland) · 2024Review
- FGF receptors mediate cellular senescence in the cystic fibrosis airway epithelium.JCI insight · 2024Article
- Lytic bacteriophages induce the secretion of antiviral and proinflammatory cytokines from human respiratory epithelial cells.PLoS biology · 2024Article
- Animals in Respiratory Research.International journal of molecular sciences · 2024Review
- Lytic bacteriophages interact with respiratory epithelial cells and induce the secretion of antiviral and proinflammatory cytokines.bioRxiv : the preprint server for biology · 2024Article
- Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats.Frontiers in pharmacology · 2024Article
- Red ginseng aqueous extract improves mucociliary transport dysfunction and histopathology in CF rat airways.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.The Lancet. Respiratory medicine · 2023Review
- Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes.Diabetes care · 2023Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 2 countries.
Susan E BirketDepartment of Medicine.
Joy M DavisDepartment of Medicine.
Courtney M Fernandez-PettyDepartment of Medicine.
Alexander G HendersonDepartment of Medicine.
Ashley M OdenDepartment of Medicine.
LiPing TangDepartment of Medicine.
Hui WenCystic Fibrosis Research Center, and.
Jeong HongDepartment of Pediatrics, Emory University, Atlanta, Georgia.
Lianwu FuCystic Fibrosis Research Center, and.
Andre ChambersHorizon Discovery Group PLC, St. Louis, Missouri; and.
Alvin FieldsHorizon Discovery Group PLC, St. Louis, Missouri; and.
Gojun ZhaoHorizon Discovery Group PLC, St. Louis, Missouri; and.
Guillermo J TearneyWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts.
Eric J SorscherCell, Developmental, and Integrated Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Steven M RoweDepartment of Medicine.
Horizon Discovery Group (United States) · USUniversity of Alabama at Birmingham · USCystic Fibrosis Research Foundation · ITEmory University · USMassachusetts General Hospital · US
Funding
UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI George Martin Solomon · 2007 to 2026
$23.0MTranslational Program in CFTR-Related Airway DiseasesR35HL135816 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROWE, STEVEN MARK · 2017 to 2022
$6.3MThe Role of Airway Mucus in Infection and InflammationR01HL153079 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BIRKET, SUSAN ELIZABETH · 2021 to 2025
$2.2MThe Mechanisms Underlying Abnormal Mucus and its Clearance in the Cystic Fibrosis RatK08HL131867 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BIRKET, SUSAN ELIZABETH · 2017 to 2021
$637kNHLBI NIH HHS K08 HL131867NHLBI NIH HHS L40 HL129387NHLBI NIH HHS R01 HL153079NHLBI NIH HHS R35 HL135816NIDDK NIH HHS P30 DK072482
Abstract
PubMed holds no abstract for this paper.
Indexed as
AminophenolsAnimalsChloride Channel AgonistsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansModels, AnimalMucusQuinolonesRatsAminophenolsChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorivacaftorQuinolonescystic fibrosisG551Divacaftormucusrat model
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.